Molecular Dynamics Simulations and Structure-Based Rational Design Lead to Allosteric HCV NS5B Polymerase Thumb Pocket 2 Inhibitor with Picomolar Cellular Replicon Potency

被引:25
作者
Hucke, Oliver [1 ]
Coulombe, Rene [1 ]
Bonneau, Pierre [1 ]
Bertrand-Laperle, Megan [1 ]
Brochu, Christian [1 ]
Gillard, James [1 ]
Joly, Marc-Andre [1 ]
Landry, Serge [1 ]
Lepage, Olivier [1 ]
Llinas-Brunet, Montse [1 ]
Pesant, Marc [1 ]
Poirier, Martin [1 ]
Poirier, Maude [1 ]
McKercher, Ginette [1 ]
Marquis, Martin [1 ]
Kukolj, George [1 ]
Beaulieu, Pierre L. [1 ]
Stammers, Timothy A. [1 ]
机构
[1] Boehringer Ingelheim Canada Ltd, Res & Dev, Laval, PQ H7S 2G5, Canada
关键词
PALLADIUM-CATALYZED ARYLATION; DEPENDENT RNA-POLYMERASE; NS3 PROTEASE INHIBITOR; CRYSTAL-STRUCTURE; BI; 201335; DISCOVERY; EFFICACY; COMBINATION; TELAPREVIR; MORTALITY;
D O I
10.1021/jm4004522
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
The design and preliminary SAR of a new series of 1H-quinazolin-4-one (QAZ) allosteric HCV NS5B thumb pocket 2 (TP-2) inhibitors was recently reported. To support optimization efforts, a molecular dynamics (MD) based modeling workflow was implemented, providing information on QAZ binding interactions with NS5B. This approach predicted a small but critical ligand-binding induced movement of a protein backbone region which increases the pocket size and improves access to the backbone carbonyl groups of Val 494 and Pro 495. This localized backbone shift was consistent with key SAR results and was subsequently confirmed by X-ray crystallography. The MD protocol guided the design of inhibitors, exploiting novel H-bond interactions with the two backbone carbonyl groups, leading to the first thumb pocket 2 NS5B inhibitor with picomolar antiviral potency in genotype (gt) 1a and 1b replicons (EC50 = 120 and 110 pM, respectively) and with EC50 <= 80 nM against gt 2-6.
引用
收藏
页码:1932 / 1943
页数:12
相关论文
共 45 条
  • [1] Crystal structure of the RNA-dependent RNA polymerase of hepatitis C virus
    Ago, H
    Adachi, T
    Yoshida, A
    Yamamoto, M
    Habuka, N
    Yatsunami, K
    Miyano, M
    [J]. STRUCTURE, 1999, 7 (11) : 1417 - 1426
  • [2] [Anonymous], 2002, Gastroenterology, V123, P2082, DOI 10.1053/gast.2002.1232082
  • [3] [Anonymous], SUCCESSFUL STRATEGIE
  • [4] [Anonymous], DISCOVERY OF A NOVEL
  • [5] New direct-acting antivirals' combination for the treatment of chronic hepatitis C
    Asselah, Tarik
    Marcellin, Patrick
    [J]. LIVER INTERNATIONAL, 2011, 31 : 68 - 77
  • [6] Beaulieu P. L., 2003, WO Patent, Patent No. [WO03/010141, 03010141]
  • [7] Structure-based design of novel HCV NS5B thumb pocket 2 allosteric inhibitors with submicromolar gt1 replicon potency: Discovery of a quinazolinone chemotype
    Beaulieu, Pierre L.
    Coulombe, Rene
    Duan, Jianmin
    Fazal, Gulrez
    Godbout, Cedrickx
    Hucke, Oliver
    Jakalian, Araz
    Joly, Marc-Andre
    Lepage, Olivier
    Llinas-Brunet, Montse
    Naud, Julie
    Poirier, Martin
    Rioux, Nathalie
    Thavonekham, Bounkham
    Kukolj, George
    Stammers, Timothy A.
    [J]. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2013, 23 (14) : 4132 - 4140
  • [8] Recent advances in the development of NS5B polymerase inhibitors for the treatment of hepatitis C virus infection
    Beaulieu, Pierre L.
    [J]. EXPERT OPINION ON THERAPEUTIC PATENTS, 2009, 19 (02) : 145 - 164
  • [9] Small molecule inhibitors of the hepatitis C virus-encoded NS5A protein
    Belda, Oscar
    Targett-Adams, Paul
    [J]. VIRUS RESEARCH, 2012, 170 (1-2) : 1 - 14
  • [10] Boceprevir, an NS3 Protease Inhibitor of HCV
    Berman, Kenneth
    Kwo, Paul Y.
    [J]. CLINICS IN LIVER DISEASE, 2009, 13 (03) : 429 - +